Repare Therapeutics’ Post

BIO-ACADEMIA: In a stride towards enhancing HER2-positive breast cancer treatment, Korean scientists at Korea University have introduced HVH-2930, an HSP90 inhibitor poised to redefine therapeutic outcomes. Click to read: https://lnkd.in/gAx3Sebz #academia #therapeutic #breastcancer #cancertreatment #inhibitor #biovoicenews

Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes. Read abstract: https://hubs.ly/Q02z9qws0 #ASCO24 #OncologyResearch #RealWorldData #OlaparibMonotherapy #PatientCare

Over the past weekend, Ripal Gandhi, M.D., FSVM, FSIR presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi highlighted RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy. View the presentation here: https://bit.ly/3LDnQz8 #CIO2023 #PancreaticCancer #LocallyAdvancedPancreaticCancer #LAPC

🔬#EMPOWERLung1 Update at 35 months: With the significant contribution of 🇹🇷 researchers ✅Strengths: 🔘Cemiplimab showed pronounced survival benefits vs. chemotherapy for advanced non-small-cell lung cancer patients with PD-L1 ≥50%. 🔘Combining cemiplimab with chemo post-progression may be a promising 2nd-line treatment. ❌Weaknesses: 🔘Treatment-related deaths in both cemiplimab (3%) & chemo groups (2%). 🩺Clinical Impact: 🔘Supports cemiplimab as a leading 1st-line therapy. 🔘Potential for combined therapy approach after progression. #LungCancer #OncologyResearch OncoAlert Mustafa Ozdogan ESMO - European Society for Medical Oncology American Society of Clinical Oncology (ASCO) Saadettin Kilickap AHMET SEZER Irfan Cicin

📣 Exciting CUTANA CUT&Tag application! Here, EpiCypher pAG-Tn5 and CUT&Tag protocol were used to study localization of cGAS in cancer cells, which helped uncover novel connections between SWI/SNF chromatin remodelers and mTORC2 signaling in chemoresistant colorectal cancer. These results provide promising new strategies for therapeutic development! https://hubs.la/Q02KB1cn0

The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies. Effects of MAGL and FAAH on tumour-immune interactions. https://lnkd.in/gNei9eiU

💡Revolutionizing Oncology through Biomarker Discovery and Validation💡 Here, I explained how biomarker discovery revolutionized cancer therapy. 🎙You can learn more from the article. here https://lnkd.in/gDVbgfMG #BiomarkerDiscovery #TargetedCancerTherapies #PrecisionMedicine #CancerResearch #PersonalizedOncology #MedicalInnovation #EarlyCancerDetection #BiomarkersInHealthcare #ClinicalTrials #CancerTreatmentAdvancements

Over the past weekend, Ripal Gandhi, M.D., FSVM, FSIR presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi highlighted RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy. View the presentation here: https://bit.ly/3LDnQz8 #CIO2023 #PancreaticCancer #LocallyAdvancedPancreaticCancer #LAPC

Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 phase III trial - AstraZeneca https://lnkd.in/eMMuCeY2

This webinar will present topics on drug interactions with prostate cancer treatment, survivorship care pathways for men on ADT and an interesting case study on complications which can occur from prostate cancer treatments. #ANZUNS #Bayer #ProstateCancer